Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics

Premium
Response Genetics announced this week that its ResponseDX: Lung and ResponseDX: Colon cancer tests are now available to “select medical institutions and practice groups” through its CLIA-registered laboratory.
 
The two tests for non-small cell lung and colon cancer are PCR-based and are intended to guide treatment decisions for patients with these diseases. “The tests are in their initial launch phase and are available only to pre-qualified institutions at this time,” the company said in a statement.
 
According to the company, during this initial launch phase, Response Genetics will gather data about the clinical utility of these genetic tests.

Filed under

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.